Linde Plc (NASDAQ: LIN)

Sector: Basic Materials Industry: Specialty Chemicals CIK: 0001707925
ROIC (Qtr) 0.11
Total Debt (Qtr) 25.19 Bn
Revenue Growth (1y) (Qtr) 5.82
Add ratio to table...

About

Linde plc, also known as LIN, is a prominent player in the industrial gases industry, holding the position of the world's largest industrial gas company. It is renowned for its technological innovations and extensive range of products. The company's offerings include atmospheric gases such as oxygen, nitrogen, and argon, as well as process gases like carbon dioxide, hydrogen, and helium. Linde's reach extends across various industries, including healthcare, chemicals and energy, manufacturing, metals and mining, food and beverage, and electronics. The...

Read more

Investment thesis

Bull case

  • Linde’s record $10 billion project backlog, excluding the $500 million in space‑related contracts, demonstrates a robust pipeline that will translate into 2.5–3 billion of revenue contributions in 2026. The company’s engineering and project‑startup efficiencies, highlighted by the 29.5% operating margin in Q4, suggest that backlog conversion rates are already exceeding historical averages. With aggressive capital deployment focused on high‑density gas facilities in Texas and Florida, Linde is positioning itself to capture a larger share of the projected 10‑plus percent growth in global launch activity. The resulting scale advantages will likely drive further price discipline and margin expansion above the long‑term 30–50 basis‑point range, reinforcing investor confidence in the company’s cost discipline. {bullet} The oxyfuel technology wins, exceeding 90 new contracts in 2025 and concentrating heavily in China, represent a high‑margin, high‑penetration opportunity that aligns with global decarbonization mandates. By enabling customers to reduce natural‑gas consumption and emissions while increasing throughput, these wins are expected to generate significant incremental cash flow that can be reinvested in back‑to‑back projects. The geographic diversity of these contracts mitigates country‑specific risk, while the strong demand in emerging markets such as India and ASEAN suggests a durable growth engine. As regulatory pressures intensify, Linde’s oxyfuel portfolio is likely to command premium pricing, further bolstering profitability. {bullet} Linde’s disciplined capital allocation, returning over $7 billion to shareholders in 2025 and projecting $5.0–5.5 billion in 2026 CapEx, illustrates a mature, shareholder‑friendly model that balances growth and value creation. The firm’s 24.2% return on capital remains well above the industrial gas industry average, indicating efficient use of invested capital and a healthy buffer for weathering macro‑economic swings. Share repurchases, buoyed by attractive share price and strong free‑cash flow, add a layer of upside for equity holders and signal management confidence in the firm’s intrinsic value. {bullet} The company’s low‑carbon progress, with 50% of its power consumption sourced from low‑carbon energy and a reduction of nearly 2 million metric tons of CO₂, positions Linde favorably amid increasing ESG scrutiny. This trajectory aligns with long‑term policy trends favoring green gas solutions and positions Linde to capture new revenue streams from clean‑hydrogen and carbon‑capture customers. The demonstrated ability to scale sustainable operations without compromising margins underscores operational resilience. {bullet} Linde’s presence in the commercial space sector, where it supplies 65–75% of global launches, is expected to deliver double‑digit growth over the next few years. The strategic investment in launch‑capable facilities and the pipeline of contracts with major launch customers such as SpaceX and Arianespace signal a secular shift toward a high‑margin, high‑frequency business. As the launch market expands to support the burgeoning satellite constellation and human‑spaceflight initiatives, Linde is well‑positioned to capture a growing share of the high‑purity gas demand inherent to these operations. {bullet} The company’s management expressed guarded confidence about 2026 guidance, yet the underlying data—projected 6–9% EPS growth, $10 billion backlog, and disciplined pricing—suggests that the market is likely underestimating the upside. By setting a conservative base‑volume assumption of 0% while still projecting strong revenue growth, management is signaling a potential upside scenario if macro‑economic conditions improve. The company’s historical track record of achieving pricing targets in line with inflation further supports a bullish outlook. {bullet} The synergy realization from the $400 million bolt‑on acquisitions completed in 2025, expected to reach 1% of sales, demonstrates Linde’s capacity to generate incremental revenue and margin enhancement through strategic acquisitions. With a 12–24 month window for full‑run‑rate synergy realization, these deals will likely contribute to both top‑line and bottom‑line growth in 2026, enhancing shareholder returns. This disciplined acquisition strategy complements organic growth initiatives, providing a balanced growth engine. {bullet} Finally, Linde’s leadership stability, with CEO Sanjiv Lamba’s decade‑long tenure and a clear six‑point growth blueprint, reinforces strategic continuity. The firm’s transparent communication, disciplined pricing discipline, and focus on high‑quality wins signal a strong governance culture that investors can trust. Given the company’s track record of outperforming peers in a cyclical industry, the bullish thesis highlights significant upside potential that the market may have overlooked.

Bear case

  • Management’s candid admission of broad‑based weakness in EMEA, with no substantive recovery catalyst on the horizon, signals a persistent downside risk to revenue growth. The region’s chemical and energy end markets have delivered negative volume growth, and pricing in Europe remains constrained despite the company’s historically strong price‑setting track record. This geographical imbalance means that even a robust Americas or APAC performance may not fully offset the erosion in the company’s largest revenue region, potentially compressing overall earnings. {bullet} Helium and rare‑gas pricing continued to deliver a 1–2% headwind to EPS in 2025, and management has explicitly stated no change is expected for 2026. Given that helium represents a low‑margin, high‑volume business, any persistent oversupply could erode pricing power and margin expansion efforts. The company’s other “other” segment, which includes helium intercompany sales, remains a drag on operating income and could limit the overall profitability of the gas business. {bullet} The company’s 2026 base‑volume guidance of 0% underscores a guarded outlook on macro‑economic conditions, and management explicitly describes the guidance language as “guarded, prudent, and conservative.” This cautious stance indicates that growth expectations are highly dependent on favorable macro‑economic outcomes that remain uncertain. Should a downturn in industrial activity or a slowdown in key end markets materialize, the company’s top‑line growth could stall or even contract. {bullet} While the backlog is record‑high, a large portion of it is contingent on project startups that are still under construction. The company disclosed that 2.5–3 billion of projects are expected to start in 2026, yet the conversion rate of backlog to revenue can be highly variable, subject to construction delays, permitting issues, and customer credit risk. Any slowdown in project start‑ups could create a gap between revenue expectations and actual performance, pressuring margins and cash flow. {bullet} Restructuring actions booked at $230 million, while generating cash payback, are structural and focus on headcount reductions in engineering. Although these actions should produce margin uplift in the second half of 2026, they also signal that the company is already operating on a constrained cost base. If macro‑economic headwinds worsen, the company may be forced to further cut costs, which could harm employee morale and execution capability. {bullet} The company’s heavy reliance on capital expenditure—17% higher in Q4 than the prior year and projected 5.0–5.5 billion in 2026—places significant pressure on free cash flow. While operating cash flow exceeded $3 billion in Q4, the CapEx commitment could strain cash reserves if earnings do not grow as projected. Any unexpected capital requirements, such as for additional space‑sector infrastructure or unforeseen project delays, could further compress cash flow and limit the ability to return capital to shareholders. {bullet} Linde’s expansion into the commercial space sector, while a high‑growth opportunity, also introduces concentration risk. The firm supplies 65–75% of global launches, making it highly dependent on a relatively small number of launch customers and launch cadence. Any slowdown in launch activity, increased competition from new entrants, or regulatory changes affecting launch operations could disproportionately impact Linde’s revenue and margin contribution from this segment. {bullet} Finally, the company’s acquisition strategy, though disciplined, is limited to bolt‑on purchases that contribute only 1% to sales in 2025. The time lag to realize synergies—12 to 24 months—means that recent acquisitions may not materially improve profitability in the near term. If the integration process encounters challenges or if target companies underperform, the expected upside from acquisitions could be delayed or reduced, further dampening growth prospects.

Consolidation Items Breakdown of Revenue (2025)

Peer comparison

Companies in the Specialty Chemicals
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 BGLC BioNexus Gene Lab Corp - - - -
2 APD Air Products & Chemicals, Inc. - - - 0.25 Bn
3 LIN Linde Plc - - - 25.19 Bn
4 MTX Minerals Technologies Inc - - - 0.96 Bn
5 ASH Ashland Inc. - - - 1.39 Bn
6 NNUP Nocopi Technologies Inc/Md/ - - - -
7 FUL Fuller H B Co - - - 2.02 Bn
8 OEC Orion S.A. - - - 0.98 Bn